Showing results (601-610 of 667) with videos related to

Sort By:
Pageof 67
Blood|August 12, 2006
Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamicsDaniel J DeAngelo, Richard M Stone, Mark L Heaney, et al.
Cancer Discovery|September 25, 2020
Resistance to Avapritinib in PDGFRA-Driven GIST Is Caused by Secondary Mutations in the PDGFRA Kinase DomainSusanne Grunewald, Lillian R Klug, Thomas Mühlenberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2014
Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trialChristopher L Corless, Karla V Ballman, Cristina R Antonescu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 30, 2023
Clinical Benefit of Avapritinib in KIT-Mutant Gastrointestinal Stromal Tumors: A Post Hoc Analysis of the Phase I NAVIGATOR and Phase I/II CS3007-001 StudiesMichael C Heinrich, Xinhua Zhang, Robin L Jones, et al.
Iscience|April 28, 2025
Improved oxygen saturation and acclimatization with bacteriotherapy at high altitudeJames J Yu, Esteban A Moya, Hunter Cheng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2008
Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology GroupMichael C Heinrich, Kouros Owzar, Christopher L Corless, et al.
The Journal of Molecular Diagnostics : JMD|July 6, 2011
Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registryCarol Beadling, Michael C Heinrich, Andrea Warrick, et al.
BMC Cancer|January 17, 2016
Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trialPeter Reichardt, George D Demetri, Hans Gelderblom, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2014
Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patientsAndrew P Garner, Joseph M Gozgit, Rana Anjum, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2008
Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinasesMichael C Heinrich, Heikki Joensuu, George D Demetri, et al.
Pageof 67